Last update Feb. 5, 2022

Mefloquine Hydrochloride

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a 4-methanolquinoline related to quinine. Indicated in the prevention and treatment of malaria. Oral administration, weekly dose (prevention) or single dose (treatment).

It is excreted in human milk in a clinically non-significant amount. (Edstein 1988)

It is an authorized medication in infants from 4 weeks of age or 5 kg of weight (BNF 2018). Since mefloquine can be safely prescribed to young infants, exposure to the small amount excreted in the mother’s milk is also safe. (CDC 2019)

Various medical societies and expert consensus consider the use of this medication safe during breastfeeding (WHO 2010), especially if infants are not premature or newborn and weigh more than 5 kg. (CDC 2019, Saito 2018, Chen 2010, WHO 2010, Adjei 2009)

Alternatives

We do not have alternatives for Mefloquine Hydrochloride since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Mefloquine Hydrochloride in other languages or writings:

Group

Mefloquine Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Mefloquine Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 85 %
Molecular weight 415 daltons
Protein Binding 98 %
VD 20 ( 13 - 41 ) l/Kg
pKa 13.8 -
Tmax 6 - 24 hours
24 - 331 hours
M/P ratio 0.16 -
Theoretical Dose 0.008 mg/Kg/d
Relative Dose 0.2 %
Ped.Relat.Dose 0.08 - 1.1 %

References

  1. CDC. Centers for Disease Control and Prevention. Tan K, Arguin PM. Chapter 4. Travel-Related Infectious Diseases. Malaria. CDC Health Information for International Travel. 2019 Full text (link to original source)
  2. Saito M, Gilder ME, McGready R, Nosten F. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf. 2018 Nov;17(11):1129-1144. Abstract Full text (link to original source) Full text (in our servers)
  3. BNF. British National Formulary for Children 2018-2019 2018
  4. AA Pharma. Mefloquine. Drug Summary. 2016 Full text (in our servers)
  5. Chen LH, Zeind C, Mackell S, LaPointe T, Mutsch M, Wilson ME. Breastfeeding travelers: precautions and recommendations. J Travel Med. 2010 Jan-Feb;17(1):32-47. Abstract Full text (link to original source) Full text (in our servers)
  6. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: WHO, 2010 2nd ed. Geneva: WHO, 2010 Full text (link to original source) Full text (in our servers)
  7. Pérez JL, Carranza C, Mateos F. Antiparasitarios. Revisión de los fármacos útiles en el tratamiento de parasitosis clásicas y emergentes. \ [Antiparasitic drugs. Review of the useful drugs in the treatment of classic and emergent parasitic diseases]. Rev Esp Quimioter. 2009 Jun;22(2):93-105. Review. Spanish. Abstract Full text (link to original source) Full text (in our servers)
  8. Edstein MD, Veenendaal JR, Hyslop R. Excretion of mefloquine in human breast milk. Chemotherapy. 1988;34(3):165-9. Abstract

Total visits

4,280

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM